Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
J-Pharma Initiates PI Trial of LAT1 Inhibitor
The bioventure company J-Pharma Co. Ltd. has initiated a PI clinical trial of JPH203, a selective inhibitor of L-type amino acid transporter 1. According to the company, no anticancer drug with this mechanism of action has been developed, so this…
To read the full story
Related Article
- J-Pharma Goes Public on TSE, Eyes Licensing of LAT1 Inhibitors
March 26, 2026
- J-Pharma’s Biliary Tract Cancer Med Hits Mark in Japan PII Study
January 24, 2023
- Ohara Obtains Exclusive Rights to Biliary Tract Cancer Drug
April 26, 2019
BUSINESS
- Daiichi-AZ, Summit Team Up on Datroway Combo in Multiple Cancers
October 5, 2026
- Taiho, Cullinan Start US Filing for Zipalertinib-Chemo Combo
October 5, 2026
- Stargardt Diagnosis System Needs Bolstering as Treatment Nears: Expert
October 5, 2026
- AstraZeneca Opens Japan Recruitment for Young Oncologist Program
October 5, 2026
- Cheplapharm to Acquire MA for Kyowa Kirin’s 5-FU Products
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…